Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients.

9514Background: Treatment of non-small cell lung cancer (NSCLC) with EGFR exon 20 mutations is an unmet medical need. Poziotinib is a potent tyrosine kinase inhibitor (TKI) of EGFR and HER2 exon 20...